Natural history of corticosteroid therapy for inflammatory bowel disease

Stephen B. Hanauer*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


To summarize, this important article describes a population-based, inception cohort of IBD patients and demonstrates that less than half of CD or UC patients in a community setting will require CS therapy. For those that do require CS, the short-term response is very good (only 16% of patients are CS-resistant); however, transitioning to an immunomodulator appears to be necessary to sustain a long-term response in CD, and possibly in UC.

Original languageEnglish (US)
Pages (from-to)93-94
Number of pages2
JournalReviews in Gastroenterological Disorders
Issue number2
StatePublished - Jan 1 2002

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Natural history of corticosteroid therapy for inflammatory bowel disease'. Together they form a unique fingerprint.

Cite this